Total | Post-COVID-19 syndrome | Non-post-COVID-19 syndrome | |
Patients (%) | n = 123 | n = 33 | n = 90 |
Gender (female) (%) | 47 (38.2%) | 17 (51.5%) | 30 (33.3%) |
Gender (male) (%) | 76 (61.8%) | 16 (48.5%) | 60 (66.7%) |
Age (years), mean ± SD | 62.1 ± 9.5 | 58.5 ± 10.6 | 63.4 ± 8.8 |
Comorbidity (%) | |||
Direct influence on COVID-19a |
85 (69.1%)
|
20 (60.6%)
|
65 (72.2%)
|
Indirect influence on COVID-19b |
38 (30.9%)
|
13 (39.4%)
|
25 (27.8%)
|
COVID severityc (%) | |||
Low |
53 (43.1%)
|
14 (42.4%)
|
39 (43.3%)
|
Low-medium |
8 (6.5%)
|
0 (0.0%)
|
8 (8.9%)
|
Medium |
24 (19.5%)
|
6 (18.2%)
|
18 (20.0%)
|
High |
38 (30.9%)
|
13 (39.4%)
|
25 (27.8%)
|
Drug treatment | |||
Antibiotics |
89 (72.4%)
|
24 (72.7%)
|
65 (72.2%)
|
Anticoagulants |
100 (81.3%)
|
25 (75.8%)
|
75 (83.3%)
|
Corticosteroids |
73 (59.3%)
|
16 (48.5%)
|
57 (63.3%)
|
Antibiotic + Anticoagulant |
71 (57.7%)
|
18 (54.5%)
|
53 (58.9%)
|
Antibiotic + Corticosteroids |
53 (43.1%)
|
13 (39.4%)
|
40 (44.4%)
|
Anticoagulant + Corticosteroid |
64 (52.0%)
|
13 (39.4%)
|
51 (56.7%)
|
Antibiotic + Anticoagulant + corticosteroid |
46 (37.4%)
|
11 (33.3%)
|
35 (38.9%)
|
Hospital stay duration (days), mean ± SD | 12.5 ± 11.3 | 10.2 ± 8.6 | 13.3 ± 12.1 |